{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:52:20Z","timestamp":1762005140070,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health &amp; Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI129873","P41GM103490","R01DK042667","R21NS095627","K08EY024645"],"award-info":[{"award-number":["R21AI129873","P41GM103490","R01DK042667","R21NS095627","K08EY024645"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fabry disease is an X-linked lysosomal storage disease caused by deficiency of \u03b1-galactosidase A. Ocular findings, such as cornea verticillata, cataracts, and retinal vascular tortuosity, serve as important diagnostic markers. We aimed to evaluate ocular phenotypes in \u03b1-galactosidase A-deficient (Fabry) rats and hypothesized that these rats would manifest ocular signs similar to those observed in patients. Slit lamp biomicroscopy was used to evaluate the cornea and lens, and retinal vasculature was examined by fluorescein angiography in WT and Fabry rats. Mass spectrometry was used to characterize and quantify ocular glycosphingolipids, and histology and electron microscopy revealed the location of the glycosphingolipid storage. We found that Fabry rats developed corneal and lenticular opacities to a statistically greater degree than WT rats. Retinal vascular morphology did not appear grossly different, but there was vascular leakage in at least one Fabry rat. Fabry rat eyes accumulated substrates of \u03b1-galactosidase A, and these \u03b1-galactosyl glycoconjugates were found in corneal keratocytes, lens fibers, and retinal vascular endothelial cells. Electron-dense lamellar inclusions were observed in keratocytes. Because Fabry rats recapitulate many ocular phenotypes observed in patients, they can be used to study disease pathogenesis and determine whether ocular findings serve as noninvasive indicators of therapeutic efficacy.<\/jats:p>","DOI":"10.1038\/s41598-019-45837-1","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T10:03:14Z","timestamp":1561716194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Rats deficient in \u03b1-galactosidase A develop ocular manifestations of Fabry disease"],"prefix":"10.1038","volume":"9","author":[{"given":"James J.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Tiemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-0590","authenticated-orcid":false,"given":"Nancy M.","family":"Dahms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3351-9779","authenticated-orcid":false,"given":"Iris S.","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"key":"45837_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","volume":"166","author":"PV Hopkins","year":"2015","unstructured":"Hopkins, P. V. et al. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. Journal of Pediatrics 166, 172\u2013177 (2015).","journal-title":"Journal of Pediatrics"},{"key":"45837_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","volume":"190","author":"BK Burton","year":"2017","unstructured":"Burton, B. K. et al. Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience. J Pediatr 190, 130\u2013135, https:\/\/doi.org\/10.1016\/j.jpeds.2017.06.048 (2017).","journal-title":"J Pediatr"},{"key":"45837_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain, D. P. Fabry disease. Orphanet J Rare Dis 5, 30, https:\/\/doi.org\/10.1186\/1750-1172-5-30 (2010).","journal-title":"Orphanet J Rare Dis"},{"key":"45837_CR4","doi-asserted-by":"publisher","first-page":"e0120814","DOI":"10.1371\/journal.pone.0120814","volume":"10","author":"S Pitz","year":"2015","unstructured":"Pitz, S. et al. Ocular signs correlate well with disease severity and genotype in Fabry disease. PLoS One 10, e0120814, https:\/\/doi.org\/10.1371\/journal.pone.0120814 (2015).","journal-title":"PLoS One"},{"key":"45837_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/bjo.2006.100602","volume":"91","author":"A Sodi","year":"2007","unstructured":"Sodi, A. et al. Ocular manifestations of Fabry\u2019s disease: data from the Fabry Outcome Survey. Br J Ophthalmol 91, 210\u2013214, https:\/\/doi.org\/10.1136\/bjo.2006.100602 (2007).","journal-title":"Br J Ophthalmol"},{"key":"45837_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.survophthal.2008.04.005","volume":"53","author":"N Samiy","year":"2008","unstructured":"Samiy, N. Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 53, 416\u2013423, https:\/\/doi.org\/10.1016\/j.survophthal.2008.04.005 (2008).","journal-title":"Surv Ophthalmol"},{"key":"45837_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/aos.12588","volume":"93","author":"HC Fledelius","year":"2015","unstructured":"Fledelius, H. C., Sandfeld, L., Rasmussen, A. K., Madsen, C. V. & Feldt-Rasmussen, U. Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement. Acta Ophthalmol 93, 258\u2013264, https:\/\/doi.org\/10.1111\/aos.12588 (2015).","journal-title":"Acta Ophthalmol"},{"key":"45837_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/archopht.1978.03910050421003","volume":"96","author":"NA Sher","year":"1978","unstructured":"Sher, N. A., Reiff, W., Letson, R. D. & Desnick, R. J. Central retinal artery occlusion complicating Fabry\u2019s disease. Arch Ophthalmol 96, 815\u2013817 (1978).","journal-title":"Arch Ophthalmol"},{"key":"45837_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10792-008-9252-0","volume":"29","author":"A Sodi","year":"2009","unstructured":"Sodi, A., Bini, A., Mignani, R., Minuti, B. & Menchini, U. Subfoveal choroidal neovascularization in a patient with Fabry\u2019s disease. Int Ophthalmol 29, 435\u2013437, https:\/\/doi.org\/10.1007\/s10792-008-9252-0 (2009).","journal-title":"Int Ophthalmol"},{"key":"45837_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/8904_2011_106","volume":"5","author":"K Nicholls","year":"2012","unstructured":"Nicholls, K., Bleasel, K. & Becker, G. Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy. JIMD Rep 5, 109\u2013112, https:\/\/doi.org\/10.1007\/8904_2011_106 (2012).","journal-title":"JIMD Rep"},{"key":"45837_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain, D. P. et al. Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med 375, 545\u2013555, https:\/\/doi.org\/10.1056\/NEJMoa1510198 (2016).","journal-title":"N Engl J Med"},{"key":"45837_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes, D. A. et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 54, 288\u2013296, https:\/\/doi.org\/10.1136\/jmedgenet-2016-104178 (2017).","journal-title":"J Med Genet"},{"key":"45837_CR13","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","volume":"94","author":"T Ohshima","year":"1997","unstructured":"Ohshima, T. et al. alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 94, 2540\u20132544 (1997).","journal-title":"Proc Natl Acad Sci USA"},{"key":"45837_CR14","doi-asserted-by":"publisher","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","volume":"96","author":"T Ohshima","year":"1999","unstructured":"Ohshima, T. et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci USA 96, 6423\u20136427 (1999).","journal-title":"Proc Natl Acad Sci USA"},{"key":"45837_CR15","doi-asserted-by":"publisher","first-page":"e99171","DOI":"10.1172\/jci.insight.99171","volume":"3","author":"JJ Miller","year":"2018","unstructured":"Miller, J. J. et al. Neuropathic pain in a Fabry disease rat model. JCI Insight 3, e99171, https:\/\/doi.org\/10.1172\/jci.insight.99171 (2018).","journal-title":"JCI Insight"},{"key":"45837_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1096\/fj.201800771R","volume":"33","author":"JJ Miller","year":"2019","unstructured":"Miller, J. J. et al. Alpha-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease. FASEB J 33, 418\u2013429, https:\/\/doi.org\/10.1096\/fj.201800771R (2019).","journal-title":"FASEB J"},{"key":"45837_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/BF00200486","volume":"233","author":"CE Margo","year":"1995","unstructured":"Margo, C. E. & Lee, A. Fixation of whole eyes: the role of fixative osmolarity in the production of tissue artifact. Graefes Arch Clin Exp Ophthalmol 233, 366\u2013370 (1995).","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"45837_CR18","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/S0021-9258(17)40221-3","volume":"252","author":"LA Murphy","year":"1977","unstructured":"Murphy, L. A. & Goldstein, I. J. Five alpha-D-galactopyranosyl-binding isolectins from Bandeiraea simplicifolia seeds. J Biol Chem 252, 4739\u20134742 (1977).","journal-title":"J Biol Chem"},{"key":"45837_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1046\/j.1440-1711.2001.00992.x","volume":"79","author":"S Kirkeby","year":"2001","unstructured":"Kirkeby, S. & Moe, D. Binding of Griffonia simplicifolia 1 isolectin B4 (GS1 B4) to alpha-galactose antigens. Immunol Cell Biol 79, 121\u2013127, https:\/\/doi.org\/10.1046\/j.1440-1711.2001.00992.x (2001).","journal-title":"Immunol Cell Biol"},{"key":"45837_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1023\/A:1015511908710","volume":"11","author":"KF Gold","year":"2002","unstructured":"Gold, K. F. et al. Quality of life of patients with Fabry disease. Qual Life Res 11, 317\u2013327 (2002).","journal-title":"Qual Life Res"},{"key":"45837_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","volume":"41","author":"M Arends","year":"2018","unstructured":"Arends, M. et al. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis 41, 141\u2013149, https:\/\/doi.org\/10.1007\/s10545-017-0095-6 (2018).","journal-title":"J Inherit Metab Dis"},{"key":"45837_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrd.2017.214","volume":"17","author":"FM Platt","year":"2018","unstructured":"Platt, F. M. Emptying the stores: lysosomal diseases and therapeutic strategies. Nat Rev Drug Discov 17, 133\u2013150, https:\/\/doi.org\/10.1038\/nrd.2017.214 (2018).","journal-title":"Nat Rev Drug Discov"},{"key":"45837_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30688-z","volume":"8","author":"G Bitirgen","year":"2018","unstructured":"Bitirgen, G., Turkmen, K., Malik, R. A., Ozkagnici, A. & Zengin, N. Corneal confocal microscopy detects corneal nerve damage and increased dendritic cells in Fabry disease. Sci Rep 8, 12244, https:\/\/doi.org\/10.1038\/s41598-018-30688-z (2018).","journal-title":"Sci Rep"},{"key":"45837_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1042\/BJ20130825","volume":"456","author":"A Taguchi","year":"2013","unstructured":"Taguchi, A. et al. A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis. Biochem J 456, 373\u2013383, https:\/\/doi.org\/10.1042\/BJ20130825 (2013).","journal-title":"Biochem J"},{"key":"45837_CR25","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1111\/aos.13541","volume":"96","author":"S Koh","year":"2018","unstructured":"Koh, S., Sakai, N., Maeda, N. & Nishida, K. Prominent regression of corneal deposits in Fabry disease 16 years after initiation of enzyme replacement therapy. Acta Ophthalmol 96, e255\u2013e256, https:\/\/doi.org\/10.1111\/aos.13541 (2018).","journal-title":"Acta Ophthalmol"},{"key":"45837_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0002-9394(72)90071-2","volume":"73","author":"RL Font","year":"1972","unstructured":"Font, R. L. & Fine, B. S. Ocular pathology in fabry\u2019s disease. Histochemical and electron microscopic observations. Am J Ophthalmol 73, 419\u2013430 (1972).","journal-title":"Am J Ophthalmol"},{"key":"45837_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.biocel.2007.10.034","volume":"40","author":"UP Andley","year":"2008","unstructured":"Andley, U. P. The lens epithelium: focus on the expression and function of the alpha-crystallin chaperones. Int J Biochem Cell Biol 40, 317\u2013323, https:\/\/doi.org\/10.1016\/j.biocel.2007.10.034 (2008).","journal-title":"Int J Biochem Cell Biol"},{"key":"45837_CR28","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1194\/jlr.R004119","volume":"51","author":"D Borchman","year":"2010","unstructured":"Borchman, D. & Yappert, M. C. Lipids and the ocular lens. J Lipid Res 51, 2473\u20132488, https:\/\/doi.org\/10.1194\/jlr.R004119 (2010).","journal-title":"J Lipid Res"},{"key":"45837_CR29","first-page":"2171","volume":"31","author":"M Ogiso","year":"1990","unstructured":"Ogiso, M. et al. Increase in lens gangliosides due to aging and cataract progression in human senile cataract. Invest Ophthalmol Vis Sci 31, 2171\u20132179 (1990).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"45837_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1113\/jphysiol.2004.068619","volume":"559","author":"R McNulty","year":"2004","unstructured":"McNulty, R. et al. Regulation of tissue oxygen levels in the mammalian lens. J Physiol 559, 883\u2013898, https:\/\/doi.org\/10.1113\/jphysiol.2004.068619 (2004).","journal-title":"J Physiol"},{"key":"45837_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","volume":"82","author":"T Lucke","year":"2004","unstructured":"Lucke, T., Hoppner, W., Schmidt, E., Illsinger, S. & Das, A. M. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab 82, 93\u201397, https:\/\/doi.org\/10.1016\/j.ymgme.2004.01.011 (2004).","journal-title":"Mol Genet Metab"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45837-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:53:19Z","timestamp":1671274399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45837-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45837"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45837-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,6,28]]},"assertion":[{"value":"28 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9392"}}